Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NTEC

Intec Pharma (NTEC) Stock Price, News & Analysis

Intec Pharma logo

About Intec Pharma Stock (NASDAQ:NTEC)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$9.15
$36.20
52-Week Range
N/A
Volume
988,300 shs
Average Volume
543,436 shs
Market Capitalization
$8.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NTEC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NTEC Stock News Headlines

Indaptus Therapeutics reports Q3 EPS (32c) vs. (47c) last year
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
X4 Pharmaceuticals, Inc. (XFOR)
INDP Indaptus Therapeutics, Inc.
See More Headlines

NTEC Stock Analysis - Frequently Asked Questions

Intec Pharma Ltd (NASDAQ:NTEC) released its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) EPS for the quarter, missing the consensus estimate of ($3.48) by $0.36.

Intec Pharma shares reverse split on Tuesday, July 27th 2021.The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Intec Pharma (NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intec Pharma investors own include FuelCell Energy (FCEL), NVIDIA (NVDA), Ovid Therapeutics (OVID), Plug Power (PLUG), SCYNEXIS (SCYX), Fortress Biotech (FBIO) and Lipocine (LPCN).

Company Calendar

Last Earnings
5/17/2021
Today
8/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NTEC
CIK
1638381
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($16.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.13 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-96.37%
Return on Assets
-68.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.34
Quick Ratio
2.34

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.18 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
898,000
Free Float
N/A
Market Cap
$8.65 million
Optionable
Optionable
Beta
0.83
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NTEC) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners